aluates Reports

$ 0.0

Automative

Global Hematological Malignancies Disease Market Research Report 2025

Published Date: September 2025

Report Code: QYRE-Auto-31N3977

Global Hematological Malignancies Disease Market Insights and Forecast to 2028

BUY CHAPTERS

Global Hematological Malignancies Disease Market Research Report 2025

Code: QYRE-Auto-31N3977

Report

September 2025

Pages:101

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Affymetrix Inc

SkylineDx

AgenaBio

Signal Genetics

Pfizer Inc

Roche

Sanofi Aventis

Cancer Genetics Inc.

Illumina Inc

NeoGenomics

Exiqon

Regulus Therapeutics

Rosetta Genomics

Sequenta

Takeda Pharma

Celgene

Amgen Inc

Ono Pharma

Abbott

BMS

Mundipharma

Novartis

MorphoSys

Hematological Malignancies Disease Market Size

The global market for Hematological Malignancies Disease was valued at US$ 42130 million in the year 2024 and is projected to reach a revised size of US$ 60330 million by 2031, growing at a CAGR of 5.3% during the forecast period.

Hematological Malignancies Disease Market

Hematological malignancies are myeloid and lymphatic tumors caused by disruption of normal hematopoietic function. They are classified into several common subtypes, generally consisting of leukemia, multiple myeloma (MM), non-Hodgkin lymphoma (NHL), and Hodgkin lymphoma (HL).

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Hematological Malignancies Disease, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hematological Malignancies Disease.

The Hematological Malignancies Disease market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Hematological Malignancies Disease market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Hematological Malignancies Disease companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Hematological Malignancies Disease Market Report

Report Metric	Details
Report Name	Hematological Malignancies Disease Market
Accounted market size in year	US$ 42130 million
Forecasted market size in 2031	US$ 60330 million
CAGR	5.3%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Chemotherapy Immunotherapy Targeted Therapy Radiotherapy Stem Cell Transplantation Others
Segment by Application	Leukemia Lymphoma Myeloma Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Affymetrix, SkylineDx, AgenaBio, Signal Genetics, Pfizer, Roche, Sanofi-Aventis, Cancer Genetics Inc, Illumina, NeoGenomics, Exiqon, Regulus Therapeutics, Rosetta Genomics, Sequenta, Takeda Pharma, Celgene, Amgen, Ono Pharma, Abbott, BMS, Mundipharma, Novartis, MorphoSys
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hematological Malignancies Disease company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Hematological Malignancies Disease Market growing?

Ans: The Hematological Malignancies Disease Market witnessing a CAGR of 5.3% during the forecast period 2025-2031.

What is the Hematological Malignancies Disease Market size in 2031?

Ans: The Hematological Malignancies Disease Market size in 2031 will be US$ 60330 million.

Who are the main players in the Hematological Malignancies Disease Market report?

Ans: The main players in the Hematological Malignancies Disease Market are Affymetrix, SkylineDx, AgenaBio, Signal Genetics, Pfizer, Roche, Sanofi-Aventis, Cancer Genetics Inc, Illumina, NeoGenomics, Exiqon, Regulus Therapeutics, Rosetta Genomics, Sequenta, Takeda Pharma, Celgene, Amgen, Ono Pharma, Abbott, BMS, Mundipharma, Novartis, MorphoSys

What are the Application segmentation covered in the Hematological Malignancies Disease Market report?

Ans: The Applications covered in the Hematological Malignancies Disease Market report are Leukemia, Lymphoma, Myeloma, Others

What are the Type segmentation covered in the Hematological Malignancies Disease Market report?

Ans: The Types covered in the Hematological Malignancies Disease Market report are Chemotherapy, Immunotherapy, Targeted Therapy, Radiotherapy, Stem Cell Transplantation, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Hematological Malignancies Disease Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Chemotherapy

1.2.3 Immunotherapy

1.2.4 Targeted Therapy

1.2.5 Radiotherapy

1.2.6 Stem Cell Transplantation

1.2.7 Others

1.3 Market by Application

1.3.1 Global Hematological Malignancies Disease Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Leukemia

1.3.3 Lymphoma

1.3.4 Myeloma

1.3.5 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Hematological Malignancies Disease Market Perspective (2020-2031)

2.2 Global Hematological Malignancies Disease Growth Trends by Region

2.2.1 Global Hematological Malignancies Disease Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Hematological Malignancies Disease Historic Market Size by Region (2020-2025)

2.2.3 Hematological Malignancies Disease Forecasted Market Size by Region (2026-2031)

2.3 Hematological Malignancies Disease Market Dynamics

2.3.1 Hematological Malignancies Disease Industry Trends

2.3.2 Hematological Malignancies Disease Market Drivers

2.3.3 Hematological Malignancies Disease Market Challenges

2.3.4 Hematological Malignancies Disease Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Hematological Malignancies Disease Players by Revenue

3.1.1 Global Top Hematological Malignancies Disease Players by Revenue (2020-2025)

3.1.2 Global Hematological Malignancies Disease Revenue Market Share by Players (2020-2025)

3.2 Global Hematological Malignancies Disease Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Hematological Malignancies Disease Revenue

3.4 Global Hematological Malignancies Disease Market Concentration Ratio

3.4.1 Global Hematological Malignancies Disease Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Hematological Malignancies Disease Revenue in 2024

3.5 Global Key Players of Hematological Malignancies Disease Head office and Area Served

3.6 Global Key Players of Hematological Malignancies Disease, Product and Application

3.7 Global Key Players of Hematological Malignancies Disease, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Hematological Malignancies Disease Breakdown Data by Type

4.1 Global Hematological Malignancies Disease Historic Market Size by Type (2020-2025)

4.2 Global Hematological Malignancies Disease Forecasted Market Size by Type (2026-2031)

5 Hematological Malignancies Disease Breakdown Data by Application

5.1 Global Hematological Malignancies Disease Historic Market Size by Application (2020-2025)

5.2 Global Hematological Malignancies Disease Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Hematological Malignancies Disease Market Size (2020-2031)

6.2 North America Hematological Malignancies Disease Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Hematological Malignancies Disease Market Size by Country (2020-2025)

6.4 North America Hematological Malignancies Disease Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Hematological Malignancies Disease Market Size (2020-2031)

7.2 Europe Hematological Malignancies Disease Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Hematological Malignancies Disease Market Size by Country (2020-2025)

7.4 Europe Hematological Malignancies Disease Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Hematological Malignancies Disease Market Size (2020-2031)

8.2 Asia-Pacific Hematological Malignancies Disease Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Hematological Malignancies Disease Market Size by Region (2020-2025)

8.4 Asia-Pacific Hematological Malignancies Disease Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Hematological Malignancies Disease Market Size (2020-2031)

9.2 Latin America Hematological Malignancies Disease Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Hematological Malignancies Disease Market Size by Country (2020-2025)

9.4 Latin America Hematological Malignancies Disease Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Hematological Malignancies Disease Market Size (2020-2031)

10.2 Middle East & Africa Hematological Malignancies Disease Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Hematological Malignancies Disease Market Size by Country (2020-2025)

10.4 Middle East & Africa Hematological Malignancies Disease Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Affymetrix

11.1.1 Affymetrix Company Details

11.1.2 Affymetrix Business Overview

11.1.3 Affymetrix Hematological Malignancies Disease Introduction

11.1.4 Affymetrix Revenue in Hematological Malignancies Disease Business (2020-2025)

11.1.5 Affymetrix Recent Development

11.2 SkylineDx

11.2.1 SkylineDx Company Details

11.2.2 SkylineDx Business Overview

11.2.3 SkylineDx Hematological Malignancies Disease Introduction

11.2.4 SkylineDx Revenue in Hematological Malignancies Disease Business (2020-2025)

11.2.5 SkylineDx Recent Development

11.3 AgenaBio

11.3.1 AgenaBio Company Details

11.3.2 AgenaBio Business Overview

11.3.3 AgenaBio Hematological Malignancies Disease Introduction

11.3.4 AgenaBio Revenue in Hematological Malignancies Disease Business (2020-2025)

11.3.5 AgenaBio Recent Development

11.4 Signal Genetics

11.4.1 Signal Genetics Company Details

11.4.2 Signal Genetics Business Overview

11.4.3 Signal Genetics Hematological Malignancies Disease Introduction

11.4.4 Signal Genetics Revenue in Hematological Malignancies Disease Business (2020-2025)

11.4.5 Signal Genetics Recent Development

11.5 Pfizer

11.5.1 Pfizer Company Details

11.5.2 Pfizer Business Overview

11.5.3 Pfizer Hematological Malignancies Disease Introduction

11.5.4 Pfizer Revenue in Hematological Malignancies Disease Business (2020-2025)

11.5.5 Pfizer Recent Development

11.6 Roche

11.6.1 Roche Company Details

11.6.2 Roche Business Overview

11.6.3 Roche Hematological Malignancies Disease Introduction

11.6.4 Roche Revenue in Hematological Malignancies Disease Business (2020-2025)

11.6.5 Roche Recent Development

11.7 Sanofi-Aventis

11.7.1 Sanofi-Aventis Company Details

11.7.2 Sanofi-Aventis Business Overview

11.7.3 Sanofi-Aventis Hematological Malignancies Disease Introduction

11.7.4 Sanofi-Aventis Revenue in Hematological Malignancies Disease Business (2020-2025)

11.7.5 Sanofi-Aventis Recent Development

11.8 Cancer Genetics Inc

11.8.1 Cancer Genetics Inc Company Details

11.8.2 Cancer Genetics Inc Business Overview

11.8.3 Cancer Genetics Inc Hematological Malignancies Disease Introduction

11.8.4 Cancer Genetics Inc Revenue in Hematological Malignancies Disease Business (2020-2025)

11.8.5 Cancer Genetics Inc Recent Development

11.9 Illumina

11.9.1 Illumina Company Details

11.9.2 Illumina Business Overview

11.9.3 Illumina Hematological Malignancies Disease Introduction

11.9.4 Illumina Revenue in Hematological Malignancies Disease Business (2020-2025)

11.9.5 Illumina Recent Development

11.10 NeoGenomics

11.10.1 NeoGenomics Company Details

11.10.2 NeoGenomics Business Overview

11.10.3 NeoGenomics Hematological Malignancies Disease Introduction

11.10.4 NeoGenomics Revenue in Hematological Malignancies Disease Business (2020-2025)

11.10.5 NeoGenomics Recent Development

11.11 Exiqon

11.11.1 Exiqon Company Details

11.11.2 Exiqon Business Overview

11.11.3 Exiqon Hematological Malignancies Disease Introduction

11.11.4 Exiqon Revenue in Hematological Malignancies Disease Business (2020-2025)

11.11.5 Exiqon Recent Development

11.12 Regulus Therapeutics

11.12.1 Regulus Therapeutics Company Details

11.12.2 Regulus Therapeutics Business Overview

11.12.3 Regulus Therapeutics Hematological Malignancies Disease Introduction

11.12.4 Regulus Therapeutics Revenue in Hematological Malignancies Disease Business (2020-2025)

11.12.5 Regulus Therapeutics Recent Development

11.13 Rosetta Genomics

11.13.1 Rosetta Genomics Company Details

11.13.2 Rosetta Genomics Business Overview

11.13.3 Rosetta Genomics Hematological Malignancies Disease Introduction

11.13.4 Rosetta Genomics Revenue in Hematological Malignancies Disease Business (2020-2025)

11.13.5 Rosetta Genomics Recent Development

11.14 Sequenta

11.14.1 Sequenta Company Details

11.14.2 Sequenta Business Overview

11.14.3 Sequenta Hematological Malignancies Disease Introduction

11.14.4 Sequenta Revenue in Hematological Malignancies Disease Business (2020-2025)

11.14.5 Sequenta Recent Development

11.15 Takeda Pharma

11.15.1 Takeda Pharma Company Details

11.15.2 Takeda Pharma Business Overview

11.15.3 Takeda Pharma Hematological Malignancies Disease Introduction

11.15.4 Takeda Pharma Revenue in Hematological Malignancies Disease Business (2020-2025)

11.15.5 Takeda Pharma Recent Development

11.16 Celgene

11.16.1 Celgene Company Details

11.16.2 Celgene Business Overview

11.16.3 Celgene Hematological Malignancies Disease Introduction

11.16.4 Celgene Revenue in Hematological Malignancies Disease Business (2020-2025)

11.16.5 Celgene Recent Development

11.17 Amgen

11.17.1 Amgen Company Details

11.17.2 Amgen Business Overview

11.17.3 Amgen Hematological Malignancies Disease Introduction

11.17.4 Amgen Revenue in Hematological Malignancies Disease Business (2020-2025)

11.17.5 Amgen Recent Development

11.18 Ono Pharma

11.18.1 Ono Pharma Company Details

11.18.2 Ono Pharma Business Overview

11.18.3 Ono Pharma Hematological Malignancies Disease Introduction

11.18.4 Ono Pharma Revenue in Hematological Malignancies Disease Business (2020-2025)

11.18.5 Ono Pharma Recent Development

11.19 Abbott

11.19.1 Abbott Company Details

11.19.2 Abbott Business Overview

11.19.3 Abbott Hematological Malignancies Disease Introduction

11.19.4 Abbott Revenue in Hematological Malignancies Disease Business (2020-2025)

11.19.5 Abbott Recent Development

11.20 BMS

11.20.1 BMS Company Details

11.20.2 BMS Business Overview

11.20.3 BMS Hematological Malignancies Disease Introduction

11.20.4 BMS Revenue in Hematological Malignancies Disease Business (2020-2025)

11.20.5 BMS Recent Development

11.21 Mundipharma

11.21.1 Mundipharma Company Details

11.21.2 Mundipharma Business Overview

11.21.3 Mundipharma Hematological Malignancies Disease Introduction

11.21.4 Mundipharma Revenue in Hematological Malignancies Disease Business (2020-2025)

11.21.5 Mundipharma Recent Development

11.22 Novartis

11.22.1 Novartis Company Details

11.22.2 Novartis Business Overview

11.22.3 Novartis Hematological Malignancies Disease Introduction

11.22.4 Novartis Revenue in Hematological Malignancies Disease Business (2020-2025)

11.22.5 Novartis Recent Development

11.23 MorphoSys

11.23.1 MorphoSys Company Details

11.23.2 MorphoSys Business Overview

11.23.3 MorphoSys Hematological Malignancies Disease Introduction

11.23.4 MorphoSys Revenue in Hematological Malignancies Disease Business (2020-2025)

11.23.5 MorphoSys Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Affymetrix Inc

SkylineDx

AgenaBio

Signal Genetics

Pfizer Inc

Roche

Sanofi Aventis

Cancer Genetics Inc.

Illumina Inc

NeoGenomics

Exiqon

Regulus Therapeutics

Rosetta Genomics

Sequenta

Takeda Pharma

Celgene

Amgen Inc

Ono Pharma

Abbott

BMS

Mundipharma

Novartis

MorphoSys

List of Tables

Table 1. Global Hematological Malignancies Disease Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Chemotherapy

Table 3. Key Players of Immunotherapy

Table 4. Key Players of Targeted Therapy

Table 5. Key Players of Radiotherapy

Table 6. Key Players of Stem Cell Transplantation

Table 7. Key Players of Others

Table 8. Global Hematological Malignancies Disease Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 9. Global Hematological Malignancies Disease Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 10. Global Hematological Malignancies Disease Market Size by Region (2020-2025) & (US$ Million)

Table 11. Global Hematological Malignancies Disease Market Share by Region (2020-2025)

Table 12. Global Hematological Malignancies Disease Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 13. Global Hematological Malignancies Disease Market Share by Region (2026-2031)

Table 14. Hematological Malignancies Disease Market Trends

Table 15. Hematological Malignancies Disease Market Drivers

Table 16. Hematological Malignancies Disease Market Challenges

Table 17. Hematological Malignancies Disease Market Restraints

Table 18. Global Hematological Malignancies Disease Revenue by Players (2020-2025) & (US$ Million)

Table 19. Global Hematological Malignancies Disease Market Share by Players (2020-2025)

Table 20. Global Top Hematological Malignancies Disease Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hematological Malignancies Disease as of 2024)

Table 21. Ranking of Global Top Hematological Malignancies Disease Companies by Revenue (US$ Million) in 2024

Table 22. Global 5 Largest Players Market Share by Hematological Malignancies Disease Revenue (CR5 and HHI) & (2020-2025)

Table 23. Global Key Players of Hematological Malignancies Disease, Headquarters and Area Served

Table 24. Global Key Players of Hematological Malignancies Disease, Product and Application

Table 25. Global Key Players of Hematological Malignancies Disease, Date of Enter into This Industry

Table 26. Mergers & Acquisitions, Expansion Plans

Table 27. Global Hematological Malignancies Disease Market Size by Type (2020-2025) & (US$ Million)

Table 28. Global Hematological Malignancies Disease Revenue Market Share by Type (2020-2025)

Table 29. Global Hematological Malignancies Disease Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 30. Global Hematological Malignancies Disease Revenue Market Share by Type (2026-2031)

Table 31. Global Hematological Malignancies Disease Market Size by Application (2020-2025) & (US$ Million)

Table 32. Global Hematological Malignancies Disease Revenue Market Share by Application (2020-2025)

Table 33. Global Hematological Malignancies Disease Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 34. Global Hematological Malignancies Disease Revenue Market Share by Application (2026-2031)

Table 35. North America Hematological Malignancies Disease Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 36. North America Hematological Malignancies Disease Market Size by Country (2020-2025) & (US$ Million)

Table 37. North America Hematological Malignancies Disease Market Size by Country (2026-2031) & (US$ Million)

Table 38. Europe Hematological Malignancies Disease Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 39. Europe Hematological Malignancies Disease Market Size by Country (2020-2025) & (US$ Million)

Table 40. Europe Hematological Malignancies Disease Market Size by Country (2026-2031) & (US$ Million)

Table 41. Asia-Pacific Hematological Malignancies Disease Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 42. Asia-Pacific Hematological Malignancies Disease Market Size by Region (2020-2025) & (US$ Million)

Table 43. Asia-Pacific Hematological Malignancies Disease Market Size by Region (2026-2031) & (US$ Million)

Table 44. Latin America Hematological Malignancies Disease Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 45. Latin America Hematological Malignancies Disease Market Size by Country (2020-2025) & (US$ Million)

Table 46. Latin America Hematological Malignancies Disease Market Size by Country (2026-2031) & (US$ Million)

Table 47. Middle East & Africa Hematological Malignancies Disease Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 48. Middle East & Africa Hematological Malignancies Disease Market Size by Country (2020-2025) & (US$ Million)

Table 49. Middle East & Africa Hematological Malignancies Disease Market Size by Country (2026-2031) & (US$ Million)

Table 50. Affymetrix Company Details

Table 51. Affymetrix Business Overview

Table 52. Affymetrix Hematological Malignancies Disease Product

Table 53. Affymetrix Revenue in Hematological Malignancies Disease Business (2020-2025) & (US$ Million)

Table 54. Affymetrix Recent Development

Table 55. SkylineDx Company Details

Table 56. SkylineDx Business Overview

Table 57. SkylineDx Hematological Malignancies Disease Product

Table 58. SkylineDx Revenue in Hematological Malignancies Disease Business (2020-2025) & (US$ Million)

Table 59. SkylineDx Recent Development

Table 60. AgenaBio Company Details

Table 61. AgenaBio Business Overview

Table 62. AgenaBio Hematological Malignancies Disease Product

Table 63. AgenaBio Revenue in Hematological Malignancies Disease Business (2020-2025) & (US$ Million)

Table 64. AgenaBio Recent Development

Table 65. Signal Genetics Company Details

Table 66. Signal Genetics Business Overview

Table 67. Signal Genetics Hematological Malignancies Disease Product

Table 68. Signal Genetics Revenue in Hematological Malignancies Disease Business (2020-2025) & (US$ Million)

Table 69. Signal Genetics Recent Development

Table 70. Pfizer Company Details

Table 71. Pfizer Business Overview

Table 72. Pfizer Hematological Malignancies Disease Product

Table 73. Pfizer Revenue in Hematological Malignancies Disease Business (2020-2025) & (US$ Million)

Table 74. Pfizer Recent Development

Table 75. Roche Company Details

Table 76. Roche Business Overview

Table 77. Roche Hematological Malignancies Disease Product

Table 78. Roche Revenue in Hematological Malignancies Disease Business (2020-2025) & (US$ Million)

Table 79. Roche Recent Development

Table 80. Sanofi-Aventis Company Details

Table 81. Sanofi-Aventis Business Overview

Table 82. Sanofi-Aventis Hematological Malignancies Disease Product

Table 83. Sanofi-Aventis Revenue in Hematological Malignancies Disease Business (2020-2025) & (US$ Million)

Table 84. Sanofi-Aventis Recent Development

Table 85. Cancer Genetics Inc Company Details

Table 86. Cancer Genetics Inc Business Overview

Table 87. Cancer Genetics Inc Hematological Malignancies Disease Product

Table 88. Cancer Genetics Inc Revenue in Hematological Malignancies Disease Business (2020-2025) & (US$ Million)

Table 89. Cancer Genetics Inc Recent Development

Table 90. Illumina Company Details

Table 91. Illumina Business Overview

Table 92. Illumina Hematological Malignancies Disease Product

Table 93. Illumina Revenue in Hematological Malignancies Disease Business (2020-2025) & (US$ Million)

Table 94. Illumina Recent Development

Table 95. NeoGenomics Company Details

Table 96. NeoGenomics Business Overview

Table 97. NeoGenomics Hematological Malignancies Disease Product

Table 98. NeoGenomics Revenue in Hematological Malignancies Disease Business (2020-2025) & (US$ Million)

Table 99. NeoGenomics Recent Development

Table 100. Exiqon Company Details

Table 101. Exiqon Business Overview

Table 102. Exiqon Hematological Malignancies Disease Product

Table 103. Exiqon Revenue in Hematological Malignancies Disease Business (2020-2025) & (US$ Million)

Table 104. Exiqon Recent Development

Table 105. Regulus Therapeutics Company Details

Table 106. Regulus Therapeutics Business Overview

Table 107. Regulus Therapeutics Hematological Malignancies Disease Product

Table 108. Regulus Therapeutics Revenue in Hematological Malignancies Disease Business (2020-2025) & (US$ Million)

Table 109. Regulus Therapeutics Recent Development

Table 110. Rosetta Genomics Company Details

Table 111. Rosetta Genomics Business Overview

Table 112. Rosetta Genomics Hematological Malignancies Disease Product

Table 113. Rosetta Genomics Revenue in Hematological Malignancies Disease Business (2020-2025) & (US$ Million)

Table 114. Rosetta Genomics Recent Development

Table 115. Sequenta Company Details

Table 116. Sequenta Business Overview

Table 117. Sequenta Hematological Malignancies Disease Product

Table 118. Sequenta Revenue in Hematological Malignancies Disease Business (2020-2025) & (US$ Million)

Table 119. Sequenta Recent Development

Table 120. Takeda Pharma Company Details

Table 121. Takeda Pharma Business Overview

Table 122. Takeda Pharma Hematological Malignancies Disease Product

Table 123. Takeda Pharma Revenue in Hematological Malignancies Disease Business (2020-2025) & (US$ Million)

Table 124. Takeda Pharma Recent Development

Table 125. Celgene Company Details

Table 126. Celgene Business Overview

Table 127. Celgene Hematological Malignancies Disease Product

Table 128. Celgene Revenue in Hematological Malignancies Disease Business (2020-2025) & (US$ Million)

Table 129. Celgene Recent Development

Table 130. Amgen Company Details

Table 131. Amgen Business Overview

Table 132. Amgen Hematological Malignancies Disease Product

Table 133. Amgen Revenue in Hematological Malignancies Disease Business (2020-2025) & (US$ Million)

Table 134. Amgen Recent Development

Table 135. Ono Pharma Company Details

Table 136. Ono Pharma Business Overview

Table 137. Ono Pharma Hematological Malignancies Disease Product

Table 138. Ono Pharma Revenue in Hematological Malignancies Disease Business (2020-2025) & (US$ Million)

Table 139. Ono Pharma Recent Development

Table 140. Abbott Company Details

Table 141. Abbott Business Overview

Table 142. Abbott Hematological Malignancies Disease Product

Table 143. Abbott Revenue in Hematological Malignancies Disease Business (2020-2025) & (US$ Million)

Table 144. Abbott Recent Development

Table 145. BMS Company Details

Table 146. BMS Business Overview

Table 147. BMS Hematological Malignancies Disease Product

Table 148. BMS Revenue in Hematological Malignancies Disease Business (2020-2025) & (US$ Million)

Table 149. BMS Recent Development

Table 150. Mundipharma Company Details

Table 151. Mundipharma Business Overview

Table 152. Mundipharma Hematological Malignancies Disease Product

Table 153. Mundipharma Revenue in Hematological Malignancies Disease Business (2020-2025) & (US$ Million)

Table 154. Mundipharma Recent Development

Table 155. Novartis Company Details

Table 156. Novartis Business Overview

Table 157. Novartis Hematological Malignancies Disease Product

Table 158. Novartis Revenue in Hematological Malignancies Disease Business (2020-2025) & (US$ Million)

Table 159. Novartis Recent Development

Table 160. MorphoSys Company Details

Table 161. MorphoSys Business Overview

Table 162. MorphoSys Hematological Malignancies Disease Product

Table 163. MorphoSys Revenue in Hematological Malignancies Disease Business (2020-2025) & (US$ Million)

Table 164. MorphoSys Recent Development

Table 165. Research Programs/Design for This Report

Table 166. Key Data Information from Secondary Sources

Table 167. Key Data Information from Primary Sources

Table 168. Authors List of This Report

List of Figures

Figure 1. Hematological Malignancies Disease Picture

Figure 2. Global Hematological Malignancies Disease Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Hematological Malignancies Disease Market Share by Type: 2024 VS 2031

Figure 4. Chemotherapy Features

Figure 5. Immunotherapy Features

Figure 6. Targeted Therapy Features

Figure 7. Radiotherapy Features

Figure 8. Stem Cell Transplantation Features

Figure 9. Others Features

Figure 10. Global Hematological Malignancies Disease Market Size by Application (2020-2031) & (US$ Million)

Figure 11. Global Hematological Malignancies Disease Market Share by Application: 2024 VS 2031

Figure 12. Leukemia Case Studies

Figure 13. Lymphoma Case Studies

Figure 14. Myeloma Case Studies

Figure 15. Others Case Studies

Figure 16. Hematological Malignancies Disease Report Years Considered

Figure 17. Global Hematological Malignancies Disease Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 18. Global Hematological Malignancies Disease Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 19. Global Hematological Malignancies Disease Market Share by Region: 2024 VS 2031

Figure 20. Global Hematological Malignancies Disease Market Share by Players in 2024

Figure 21. Global Top Hematological Malignancies Disease Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hematological Malignancies Disease as of 2024)

Figure 22. The Top 10 and 5 Players Market Share by Hematological Malignancies Disease Revenue in 2024

Figure 23. North America Hematological Malignancies Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. North America Hematological Malignancies Disease Market Share by Country (2020-2031)

Figure 25. United States Hematological Malignancies Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. Canada Hematological Malignancies Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Europe Hematological Malignancies Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Europe Hematological Malignancies Disease Market Share by Country (2020-2031)

Figure 29. Germany Hematological Malignancies Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. France Hematological Malignancies Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. U.K. Hematological Malignancies Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Italy Hematological Malignancies Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Russia Hematological Malignancies Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Nordic Countries Hematological Malignancies Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Asia-Pacific Hematological Malignancies Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Asia-Pacific Hematological Malignancies Disease Market Share by Region (2020-2031)

Figure 37. China Hematological Malignancies Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Japan Hematological Malignancies Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. South Korea Hematological Malignancies Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Southeast Asia Hematological Malignancies Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. India Hematological Malignancies Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Australia Hematological Malignancies Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Latin America Hematological Malignancies Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Latin America Hematological Malignancies Disease Market Share by Country (2020-2031)

Figure 45. Mexico Hematological Malignancies Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Brazil Hematological Malignancies Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Middle East & Africa Hematological Malignancies Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Middle East & Africa Hematological Malignancies Disease Market Share by Country (2020-2031)

Figure 49. Turkey Hematological Malignancies Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 50. Saudi Arabia Hematological Malignancies Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 51. UAE Hematological Malignancies Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 52. Affymetrix Revenue Growth Rate in Hematological Malignancies Disease Business (2020-2025)

Figure 53. SkylineDx Revenue Growth Rate in Hematological Malignancies Disease Business (2020-2025)

Figure 54. AgenaBio Revenue Growth Rate in Hematological Malignancies Disease Business (2020-2025)

Figure 55. Signal Genetics Revenue Growth Rate in Hematological Malignancies Disease Business (2020-2025)

Figure 56. Pfizer Revenue Growth Rate in Hematological Malignancies Disease Business (2020-2025)

Figure 57. Roche Revenue Growth Rate in Hematological Malignancies Disease Business (2020-2025)

Figure 58. Sanofi-Aventis Revenue Growth Rate in Hematological Malignancies Disease Business (2020-2025)

Figure 59. Cancer Genetics Inc Revenue Growth Rate in Hematological Malignancies Disease Business (2020-2025)

Figure 60. Illumina Revenue Growth Rate in Hematological Malignancies Disease Business (2020-2025)

Figure 61. NeoGenomics Revenue Growth Rate in Hematological Malignancies Disease Business (2020-2025)

Figure 62. Exiqon Revenue Growth Rate in Hematological Malignancies Disease Business (2020-2025)

Figure 63. Regulus Therapeutics Revenue Growth Rate in Hematological Malignancies Disease Business (2020-2025)

Figure 64. Rosetta Genomics Revenue Growth Rate in Hematological Malignancies Disease Business (2020-2025)

Figure 65. Sequenta Revenue Growth Rate in Hematological Malignancies Disease Business (2020-2025)

Figure 66. Takeda Pharma Revenue Growth Rate in Hematological Malignancies Disease Business (2020-2025)

Figure 67. Celgene Revenue Growth Rate in Hematological Malignancies Disease Business (2020-2025)

Figure 68. Amgen Revenue Growth Rate in Hematological Malignancies Disease Business (2020-2025)

Figure 69. Ono Pharma Revenue Growth Rate in Hematological Malignancies Disease Business (2020-2025)

Figure 70. Abbott Revenue Growth Rate in Hematological Malignancies Disease Business (2020-2025)

Figure 71. BMS Revenue Growth Rate in Hematological Malignancies Disease Business (2020-2025)

Figure 72. Mundipharma Revenue Growth Rate in Hematological Malignancies Disease Business (2020-2025)

Figure 73. Novartis Revenue Growth Rate in Hematological Malignancies Disease Business (2020-2025)

Figure 74. MorphoSys Revenue Growth Rate in Hematological Malignancies Disease Business (2020-2025)

Figure 75. Bottom-up and Top-down Approaches for This Report

Figure 76. Data Triangulation

Figure 77. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Hematological Malignancies Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Hematological Malignancy Treatment Market Research Report 2025

AI for Cancer Diagnosis Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Chronic Graft versus host Disease cGVHD Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Molecular Diagnosis of Tumors Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Still s Disease Treatment Market Research Report 2025

Novel Drug Delivery Systems for Cancer Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Cancer Therapeutics and Biotherapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Diagnostic Guidewire Market Research Report 2024

Sickle Cell Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Biotherapeutics Cell Line Development Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Non Small Cell Lung Cancer Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Lymphoma Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Treatment Planning Software Market Research Report 2025

Radiation Therapy Treatment Planning System Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Gynecological Cancers Drug Market Research Report 2025

Rheumatology Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Prostate Cancer Diagnostics and Therapy Market Research Report 2024

Global Kidney Cancer Diagnosis Market Research Report 2025

RELATED REPORTS

Global Hormonal Therapy for Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-5L19798

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Cancer Insurance Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-28I6901

Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-22R9736

Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Drugs for Differentiated Thyroid Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-29A2598

Tue Sep 09 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions